Anti-Hepatitis B Virus Core Antigen, IgG Fraction, Polyclonal
1mg
$425.00
Skip to product information
Anti-Hepatitis B Virus Core Antigen, IgG Fraction, Polyclonal
Catalog no.
HBP-023-9
$425.00
Anti-hepatitis B-core IgG fraction is a polyclonal antibody raised in rabbit against purified recombinant hepatitis B-core . It is purified using Protein G.
- Storage: Store at -20°C.
- Stability: At least 1 year at -20°C.
- Biological activity: This polyclonal antibody recognizes recombinant hepatitis B-core by Western analysis and ELISA.
- Formulation: IgG fraction. Frozen liquid. 1.0 mg/mL. Formulated in 0.1 M Tris-HCl (pH 7.5)
Publications using Austral Biologicals HBP-023-9
The following scientific publications report use of Austral Biologicals HBP-023-9:
- Hepatitis B virus covalently closed circular DNA formation in murine hepatic cells uncovers a late entry block. Hong et al., Proc Natl Acad Sci U S A 123(17):e2603476123 (2026).
- Development of a Novel Human Hepatoma Cell Line Supporting the Replication of a Recombinant HBV Genome with a Reporter Gene. Kawase et al., Viruses 18(2):187 (2026).
- Netrin-1 inhibits the attachment and internalization of Hepatitis B virus for hepatocyte infection. Wang et al., PLoS Pathog 21(12):e1013776 (2025).
- Gut microbes associated with functional cure of chronic hepatitis B. Honda et al., Hepatol Int 19(3):519-528 (2025).
- Antiviral effect of peptoids on hepatitis B virus infection in cell culture. Murayama et al., Antiviral Res 223:105821 (2024).
- Functional involvement of endothelial lipase in hepatitis B virus infection. Shirasaki et al., Hepatol Commun 7(9):e0206 (2023).
- Production and Purification of Cell Culture-generated Hepatitis B Virus by Transient Transfection and Density Gradient. Murayama et al., Bio Protoc 13(14):e4779 (2023).
- An RNA-based system to study hepatitis B virus replication and evaluate antivirals. Yu et al., Sci Adv 9(15):eadg6265 (2023).
- Live Cell Imaging Reveals HBV Capsid Translocation from the Nucleus To the Cytoplasm Enabled by Cell Division. Romero et al., mBio 14(2):e0330322 (2023).
- Identification of neutralizing epitopes in the preS2 domain of the hepatitis B virus. Yato et al., Virus Res 323:199014 (2023).
- Neutralization of hepatitis B virus with vaccine-escape mutations by hepatitis B vaccine with large-HBs antigen. Washizaki et al., Nat Commun 13(1):5207 (2022).
- MafF Is an Antiviral Host Factor That Suppresses Transcription from Hepatitis B Virus Core Promoter. Ibrahim et al., J Virol 95(15):e0076721 (2021).
- A Combination of Human Broadly Neutralizing Antibodies against Hepatitis B Virus HBsAg with Distinct Epitopes Suppresses Escape Mutations. Wang et al., Cell Host Microbe 28(2):335-349.e6 (2020).
- Expansion, in vivo-ex vivo cycling, and genetic manipulation of primary human hepatocytes. Michailidis et al., Proc Natl Acad Sci U S A 117(3):1678-1688 (2020).
- Effects of Moloney Leukemia Virus 10 Protein on Hepatitis B Virus Infection and Viral Replication. Puray-Chavez et al., Viruses 11(7):E651 (2019).
- Novel Hepatitis B Virus Capsid-Targeting Antiviral That Aggregates Core Particles and Inhibits Nuclear Entry of Viral Cores. Huber et al., ACS Infect Dis 5(5):750-758 (2019).
- The Heteroaryldihydropyrimidine Bay 38-7690 Induces Hepatitis B Virus Core Protein Aggregates Associated with Promyelocytic Leukemia Nuclear Bodies in Infected Cells. Huber et al., mSphere 3(2):e00131-18 (2018).
- A robust cell culture system supporting the complete life cycle of hepatitis B virus. Michailidis et al., Sci Rep 7(1):16616 (2017).
- Hepatitis B Virus Polymerase Localizes to the Mitochondria, and Its Terminal Protein Domain Contains the Mitochondrial Targeting Signal. Unchwaniwala et al., J Virol 90(19):8705-8719 (2016).
- Genetically altering the thermodynamics and kinetics of hepatitis B virus capsid assembly has profound effects on virus replication in cell culture. Tan et al., J Virol 87(6):3208-3216 (2013).